We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Exelixis Inc | NASDAQ:EXEL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.99% | 21.90 | 16.00 | 22.50 | 22.47 | 21.732 | 22.21 | 2,475,481 | 05:00:10 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Exelixis Inc. rose more than 20% on Monday after a Phase 3 study evaluating its cancer drug Cabometyx in combination with Bristol-Myers Squibb Co.'s Opdivo in the most common type of kidney cancer in adults met its main endpoints.
The companies said the study met the primary endpoint of significantly improving progression-free survival, as well as secondary endpoints of overall survival and objective response rate, compared to sunitinib in patients with previously untreated advanced or metastatic renal-cell carcinoma.
Exelixis, an Alameda, Calif., biopharmaceutical company in early 2017 announced plans to work with Bristol-Myers to study Cabometyx with Opdivo, either alone or in combination with Bristol's Yervoy.
Shares of Exelixis were recently up 23.2% to $23.95, a new 52-week high, in early trading Monday. Bristol-Myers shares rose 2.3% to $62.02.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 20, 2020 10:12 ET (14:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Exelixis Chart |
1 Month Exelixis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
